Abu Dhabi-based Novel Foods to develop $500mn biotech production site

Abu Dhabi-based Novel Foods to develop $500mn biotech production site

Novel Foods Group, the Abu Dhabi-based global pioneer in the alternative proteins sector, together with several esteemed global engineering companies have announced a landmark agreement to commence the planning phase of a $500mn biotech production site located in the UAE. The agreement was signed between Novel Foods, Glatt Group, BioEngineering AG, and CB Consultancy AG […]Novel Foods Group, the Abu Dhabi-based global pioneer in the alternative proteins sector, together with several esteemed global engineering companies have announced a landmark agreement to commence the planning phase of a $500mn biotech production site located in the UAE.

The agreement was signed between Novel Foods, Glatt Group, BioEngineering AG, and CB Consultancy AG during the inaugural Healthy Innovation Conference (HiConf) held in Dubai.

The new biotech production site will focus on the development of brazzein, a natural sweet protein with a genuine sugar taste that is several thousand times sweeter than traditional sugar (sucrose). The commercial applications of brazzein extend across various sectors, including beverages, confectionery, bakery, as well as dairy and ice cream.

The growing use of brazzein comes at a time when the global alternative sugar market is growing faster than the traditional sugar market, with a yearly growth rate of approximately 5 percent